Uzm. Dr. Alper Türkel

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Current Oncology, 2026

DOI 10.3390/curroncol33060365 PMID 42346265 Texte intégral en libre accèsSource : OpenAlex

Survival Outcomes and Recurrence Patterns of Early-Stage HER2-Positive Breast Cancer Patients on Adjuvant T-DM1 Treatment: Turkish Oncology Group (TOG) Study

Clinical Breast Cancer, 2026

DOI 10.1016/j.clbc.2025.11.014 PMID 41456513 Source : ORCID

Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy

Cancers, 2026

DOI 10.3390/cancers18142302 PMID 42512369 Texte intégral en libre accèsSource : ORCID

Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer

Journal of Oncology Pharmacy Practice, 2026

DOI 10.1177/10781552231156521 PMID 36760158 11 citations (OpenAlex) Source : ORCID

Clinical significance of the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score as a prognostic indicator in early-stage colon cancer

Discover Oncology, 2026

DOI 10.1007/s12672-026-05706-6 Texte intégral en libre accèsSource : ORCID

Evaluation of the Prognostic Importance of Gustave Roussy Immune Score in Hepatocellular Cancer Etiological Subtypes

Turkish Journal of Clinics and Laboratory, 2026

DOI 10.18663/tjcl.1810106 Texte intégral en libre accèsSource : ORCID

Predictors of burnout and secondary traumatic stress in medical oncologists: the role of empathy and dispositional mindfulness

BMC Health Services Research, 2026

DOI 10.1186/s12913-026-14002-6 PMID 41501812 Texte intégral en libre accèsSource : OpenAlex

Distinct fatigue profiles and psychological mechanisms among breast cancer survivors: A latent profile and mediation analysis

Dusunen Adam The Journal of Psychiatry and Neurological Sciences, 2026

DOI 10.14744/dajpns.2026.00322 PMID 42460117 Texte intégral en libre accèsSource : OpenAlex

PRR11 expression in early ER+/HER2‑low breast cancer: Association with estrogen receptor positivity and exploratory analysis of prognostic significance

Oncology Letters, 2026

DOI 10.3892/ol.2026.15766 PMID 42500608 Texte intégral en libre accèsSource : OpenAlex

Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

International Journal of Cancer, 2025

DOI 10.1002/ijc.70213 PMID 41147655 3 citations (Europe PMC) Source : OpenAlex

Comparative Outcomes of Surgery and Chemoradiotherapy After Neoadjuvant Chemotherapy in Stage II–III Bladder Cancer

The European Research Journal, 2025

DOI 10.18621/eurj.1807684 Texte intégral en libre accèsSource : OpenAlex

Investigation of systemic treatment responses and prognostic factors in metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs)

Journal of Health Sciences and Medicine, 2025

DOI 10.32322/jhsm.1744286 Texte intégral en libre accèsSource : ORCID

Investigation of the prevalence of HER2-ultralow and the effects of HER2 status (HER2-null vs. HER2-ultralow) on survival in HER2-negative early-stage breast cancer

Clinical and Translational Oncology, 2025

DOI 10.1007/s12094-025-04095-6 PMID 41134440 Source : ORCID

Predictive value of progesterone receptor in advanced-stage breast cancer patients treated with CDK4/6 inhibitors

Anatolian Current Medical Journal, 2025

DOI 10.38053/acmj.1670333 2 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

The mediating effect of intrusive rumination on the relationship between illness uncertainty and fear of cancer recurrence in breast cancer survivors

BMC Women s Health, 2025

DOI 10.1186/s12905-025-03580-y PMID 39891181 9 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Albumin-bilirubin (ALBI) and Platelet-ALBI (PALBI) Grades: Novel Prognostic Factors for Cholangiocellular Carcinoma

In Vivo, 2025

DOI 10.21873/invivo.14098 PMID 40877181 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

“Pre-Treatment“ and “Post-Treatment” Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment?

Medicina, 2025

DOI 10.3390/medicina61061100 PMID 40572788 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Psychometric properties of the Turkish version of the demoralization Scale-II and the association between demoralization and sociodemographic and disease-related factors in Turkish cancer patients

BMC Psychology, 2025

DOI 10.1186/s40359-025-02765-2 PMID 40275380 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Unilateral facial nerve paralysis following prolonged weekly paclitaxel therapy: a rare case of cranial neurotoxicity with diagnostic challenges

Journal of Chemotherapy, 2025

DOI 10.1080/1120009x.2025.2538945 PMID 40719000 1 citation (OpenAlex) Source : OpenAlex

The relationship between PRR11 expression and prognosis in early ER+/HER2 low breast cancer.

Journal of Clinical Oncology, 2025

DOI 10.1200/jco.2025.43.16_suppl.e15154 Source : OpenAlex

Association of TILs and HER2-low status with pathological response in triple-negative breast cancer

Medicine, 2025

DOI 10.1097/md.0000000000043971 PMID 40826749 Texte intégral en libre accèsSource : OpenAlex

The Prognostic Impact of HER2 Status and Survival Outcomes in Metastatic Triple Negative Breast Cancer

In Vivo, 2025

DOI 10.21873/invivo.14160 PMID 41167699 Texte intégral en libre accèsSource : OpenAlex

METASTATIK ÜÇLÜ NEGATIF MEME KANSERINDE HER2 DURUMUNUN (HER2- NEGATIF/HER2-LOW) PROGNOSTIK DEĞERI VE SAĞKALIMA OLAN ETKISININ ARAŞTIRILMASI

Kocaeli Üniversitesi - AVESİS, 2025

Texte intégral en libre accèsSource : OpenAlex

Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study

Cancers, 2024

DOI 10.3390/cancers16193389 PMID 39410009 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

Scientific Reports, 2024

DOI 10.1038/s41598-024-75293-5 PMID 39384975 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer

Future Oncology, 2024

DOI 10.1080/14796694.2024.2432850 PMID 39589751 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

Effects of BRCA variation on prognosis in patients with nonmetastatic breast cancer

Annals of Human Genetics, 2024

DOI 10.1111/ahg.12577 PMID 39207234 Texte intégral en libre accèsSource : ORCID

Impact of the CPS-EG score as a new prognostic biomarker in triple-negative breast cancer patients who received neoadjuvant chemotherapy

BMC Cancer, 2024

DOI 10.1186/s12885-024-13100-0 PMID 39478493 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Prognostic factors in non-metastatic HER2 ‘low’ and HER2 ‘negative’ breast cancer: single institute experience

Wiener klinische Wochenschrift, 2024

DOI 10.1007/s00508-023-02315-z PMID 38180508 1 citation (OpenAlex) Source : OpenAlex

Investigation of Clinical Course and Possible Drug Interactions in Patients with Multiple Sclerosis and Breast Cancer

Journal of College of Physicians And Surgeons Pakistan, 2024

DOI 10.29271/jcpsp.2024.07.842 PMID 38978252 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

443P Efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow-involved metastatic breast cancer

Annals of Oncology, 2023

DOI 10.1016/j.annonc.2023.09.619 Texte intégral en libre accèsSource : OpenAlex

Anti-Neoplastik İlaçlar

Akademisyen Kitabevi eBooks, 2023

DOI 10.37609/akya.2429 Texte intégral en libre accèsSource : ORCID

Adjuvant Capecitabine after Neoadjuvant Chemotherapy in Triple Negative Breast Cancer with Lymph Node Metastasis

Journal of the College of Physicians and Surgeons Pakistan, 2023

DOI 10.29271/jcpsp.2023.09.1012 PMID 37691363 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID

Vortex keratopathy associated with ribociclib

Journal of Oncology Pharmacy Practice, 2023

DOI 10.1177/10781552221101799 PMID 35570741 10 citations (OpenAlex) Source : ORCID

Gemcitabine-associated digital necrosis in metastatic breast cancer

Journal of Oncology Pharmacy Practice, 2023

DOI 10.1177/10781552231182356 PMID 37309162 4 citations (Europe PMC) Source : ORCID

288P Prognostic factors in nonmetastatic HER2 ‘low’ & HER2 ‘negative’ breast cancer: Single institute experience

Annals of Oncology, 2023

DOI 10.1016/j.annonc.2023.09.485 Texte intégral en libre accèsSource : OpenAlex